Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) presented interim results from a phase 1 study with its novel small molecule factor D inhibitor, ACH-4471, at the 21st …
With summer approaching, most of the major brokerage firms are making some changes and additions to their firms top stock ideas. At one of …
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced the initiation of a phase 1 study with ACH-4471, the Company’s first orally-administered, highly potent and specific small molecule …
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced the addition of two members to the senior management team.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that a submitted abstract has been accepted for oral presentation at the 57th Annual Meeting of the American Society …
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced today that Alios Biopharma Inc.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced additional interim results from a Phase 2 study evaluating odalasvir (also known as ACH-3102), a NS5A inhibitor, in combination …
A number of Wall Street analysts weighed in on their favorite stocks this morning before market open. Below are the most notable analyst …
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that Alios Biopharma Inc.
Achillion Pharmaceuticals, Inc. Early in the week, we saw Achillion Pharmaceuticals, Inc.
